Derived from ketamine, Spravato® is a breakthrough nasal spray for treatment-resistant depression that helps to escape negative thought patterns and consolidate new pathways.
Covered by insurance
Offers rapid relief
Easy, quick scheduling — can connect today
Therapy, medication management, and innovative treatments in one place
Expertly trained, empathetic care team
Covered by most major insurance companies
We are a team to dedicated to support you at every step
I’m less on edge and able to handle any situations that may arise without getting overly emotional about things. I think that’s been a big day to day change that I’ve experienced from Spravato.
All the staff at the clinic goes above and beyond. They truly care and take their time to make sure I understand everything and am comfortable.
[Heading] has absolutely changed my life! My body heals faster. I actually feel motivation, and best of all, I am living instead of existing.
There are several differences between Spravato® and ketamine, though more data is needed to fully understand how both work. On a basic level, Spravato® is the brand name for the compound esketamine, which is derived from isolating one component of ketamine. Ketamine has a longer history, as well, though it’s not FDA-approved to treat depression. That brings us to a key difference in terms of access and cost: Spravato® is covered by insurance, while ketamine is not. Clinical trials have shown a 69% response rate and 52% remission rate in patients treated with Spravato®.
Although the exact mechanism of action is not yet known, Spravato® is thought to create new connections in the brain by targeting the glutamate system, which is responsible for facilitating communication between nerve cells. This is referred to as neuroplasticity — the ability of the brain to change and adapt. By increasing neuroplasticity, Spravato® appears to help behavioral and cognitive changes occur more rapidly in patients with treatment-resistant depression.
If Spravato® treatment is not covered by your insurance plan, we encourage you to consider intramuscular ketamine as an alternative, more affordable treatment. If you choose to self-pay for Spravato®, the cost will likely vary based on dosage and the current retail price, but typically lands between $800-$900 per treatment, in addition to the cost of office visits.
Spravato® is the brand name for esketamine (a version of ketamine) nasal spray, which is prescribed as a fast-acting treatment for treatment-resistant depression. At Heading, we offer Spravato® to patients who qualify under their insurance plan and in accordance with FDA requirements. Most insurance companies require at least two prior antidepressant trials, and for patients to be taking an oral antidepressant, during the course of Spravato® treatment.